Company / Operating Margin
Lineage Cell Therapeutics, Inc. Operating Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-251.6%
FY2025
5-year range
-1448.4% / -226.1%
FY2021-FY2025
Trend
-11.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin has fluctuated over the past 10 years, ranging from -1448.4% in FY2021 to -226.1% in FY2024.
Based on SEC 10-K filings.
-251.6% in FY2025 with a 5-year CAGR of +854.4%.
Improved from -276.5% to -251.6% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- +882.1pp
- 5-Year Change
- +854.4pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin decreased 11.3% year-over-year.
- Peak operating margin was recorded in FY2024.
- Lowest operating margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -251.6% | -11.3% |
| FY2024 | -226.1% | +18.2% |
| FY2023 | -276.5% | +75.6% |
| FY2022 | -1133.6% | +21.7% |
| FY2021 | -1448.4% | -31.0% |
| FY2020 | -1106.0% | -32.0% |
| FY2019 | -837.9% | +25.5% |
| FY2018 | -1125.0% | -20.3% |
| FY2017 | -935.3% | +3.2% |
| FY2016 | -966.5% | +23.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026